Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | August 15, 2026 | August 18, 2026 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,499 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 722 · Balance 12,762 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2026-08-17 · Sale · Disposed 263 · Balance 12,499 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 783 |
Reported balance
After 2026-08-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-15 · Exercise / conversion · Disposed 390 · Balance 783 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,993 |
Reported balance
After 2026-08-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-15 · Exercise / conversion · Disposed 332 · Balance 1,993 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2024 Filed Feb 17, 2024 02:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 822,580 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016710 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 822,580 Underlying: Common Stock · 822,580 shares Expires 2034-02-13 F5 · derivative.exercise_date: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 637,500 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016710 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 637,500 Underlying: Common Stock · 637,500 shares Expires 2034-02-13 F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 8,552 | $1.35 | $11,545.20 |
DisclosureSEC source: 0000899243-23-020080 · doc4.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,620 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 4, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.385, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 27,838 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020080 · doc4.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,837 Underlying: Common Stock · 27,838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 27,838 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020080 · doc4.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $5.00 Strike: $9.92 | $3,413.91 |
DisclosureSEC source: 0001415889-23-012132 · form4-08112023_040813.xml · derivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2032-05-25 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $6.64 Strike: $8.28 | $4,537.78 |
DisclosureSEC source: 0001415889-23-012132 · form4-08112023_040813.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2033-05-18 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:20 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-23-008493 · form4-05222023_040505.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2033-05-18 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024. Read SEC document |
| April 27, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 55,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020080 · doc4.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,675 Underlying: Common Stock · 55,675 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-23-004206 · doc4.xml · derivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-02-02 F3 · derivative.exercise_date: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004206 · doc4.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 23:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantCOMMON STOCK | 63,492 | $3.15 | $199,999.80 |
DisclosureSEC source: 0000899243-22-025509 · doc4.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,334 Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:01 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-22-005831 · form4-05272022_050545.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0000899243-22-005315 · doc4.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 11:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $9.97 Strike: $9.97 | $88,613.36 |
DisclosureSEC source: 0001415889-21-003237 · form4-06282021_070602.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:50 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0000899243-21-005245 · doc4.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,000,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-002423 · doc4.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · President CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 21:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002213 · doc4.xml · derivative · entry 2 Shaff Eric D. · CIK 0001643734 · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units are fully vested and do not have an expiration date. F2 · derivative.expiration_date: The restricted stock units are fully vested and do not have an expiration date. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 21:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002213 · doc4.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 23:52 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 4,378 | $5.75 | $25,187.51 |
DisclosureSEC source: 0000899243-19-002138 · doc4.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,842 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $5.75 to $5.8321. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 23:52 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002138 · doc4.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 12,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020. F4 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 23:52 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-002138 · doc4.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 23:52 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 275,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0000899243-19-002138 · doc4.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2029-01-24 F3 · derivative.exercise_date: The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 120,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0000899243-18-002333 · doc4.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: COMMON STOCK · 120,000 shares Expires 2028-01-29 F3 · derivative.exercise_date: The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002333 · doc4.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: COMMON STOCK · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. F2 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 2,780 | $11.02 | $30,635.60 |
DisclosureSEC source: 0000899243-18-002333 · doc4.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,220 Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 8,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002333 · doc4.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:55 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002126 · doc4.xml · derivative · entry 2 Shaff Eric D. · CIK 0001643734 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. F3 · derivative.expiration_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:55 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0000899243-17-002126 · doc4.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 26, 2018. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.